Comparative Pharmacology
Head-to-head clinical analysis: KESIMPTA versus LEQEMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KESIMPTA versus LEQEMBI.
KESIMPTA vs LEQEMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid beta, reducing amyloid plaques in the brain.
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
10 mg/kg intravenously every 2 weeks, administered over approximately 1 hour.
None Documented
None Documented
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Terminal half-life approximately 7.6 days (range 5-12 days) after multiple doses; supports monthly dosing.
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Primarily catabolized to amino acids; not excreted renally or hepatically in unchanged form.
Category C
Category C
Monoclonal Antibody, Anti-CD20
Monoclonal Antibody